product name PD-1/PD-L1 Inhibitor 3
Description: PD-1/PD-L1 Inhibitor 3 is a Macrocyclic inhibitor of PD-1/PD-L1 interaction. PD-1/PD-L1 inhibitor 3 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (PD-1) with its ligand protein (PD-L1) and with CD80. PD-1/PD-L1 inhibitor 3 was also found to act as an immunomodulator. In addition, PD-1/PD-L1 Inhibitor 3 was found to have highly efficacious binding to PD-L1 and promote the increased functional activities of T cells. Therefore, PD-1/PD-L1 inhibitor 3 could be regarded as a promising therapeutic treatment of cancer and infectious diseases, such as hepatitis C.
References: Patent, Pub. No.:WO/2014/151634
1852.17
Formula
C89H126N24O18S
CAS No.
1629654-95-0
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (54 mM)
Water: <1 mg/mL
Ethanol: 100 mg/mL (54 mM)
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: PD-1/PD-L1 Inhibitor 3 is capable of inhibiting the interaction of PD-L1 with PD-1 and with CD80. It has highly efficacious binding to PD-L1 and promotes enhanced T cell functional activity. PD-1/PD-L1 inhibitor 3 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (PD-1) with its ligand protein (PD-L1) and with CD80. PD-1/PD-L1 inhibitor 3 was also found to act as an immunomodulator. In addition, PD-1/PD-L1 Inhibitor 3 was found to have highly efficacious binding to PD-L1 and promote the increased functional activities of T cells. Therefore, PD-1/PD-L1 inhibitor 3 could be regarded as a promising therapeutic treatment of cancer and infectious diseases, such as hepatitis C Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Patent, Pub. No.:WO/2014/151634 |
